SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LTK007 who wrote (1033)5/17/1998 9:17:00 PM
From: Andreas Helke  Read Replies (1) of 2135
 
I pretty much expected that angiostatin and endostatin would be tested in humans as soon as possible. If all goes well we may know if those angiogenesis inhibitors work in humans even before EntreMed finishes preclinical development and toxicology testing and files its IND.

I had hoped that I would have some more time to accumulate some more cheap EntreMed shares and to decide if it would be prudent to lighten up on Agouron and Ligand which are the cancer biotechs were I have really big positions now. But I do now fear that EntreMed will stay expensive until we know that those angiogenesis inhibitors are not suitable drugs. If that happens I would no longer be interested in EntreMed stock. But even if the preliminary tests do not work well there is still the chance that the drug candidates turn out to be successful drugs in some cancers during the regular clinical development.

Andreas
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News